{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:16:04Z","timestamp":1790496964611,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.kint.2017.02.035","type":"journal-article","created":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T09:45:16Z","timestamp":1498297516000},"page":"306-312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":122,"title":["Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease"],"prefix":"10.1016","volume":"92","author":[{"given":"Mai","family":"Sugahara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2017.02.035_bib1","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2017.02.035_bib2","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Dr\u00fceke","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2017.02.035_bib3","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A\u00a0trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2017.02.035_bib4","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nrneph.2015.82","article-title":"Anaemia in kidney disease: harnessing hypoxia responses for therapy","volume":"11","author":"Koury","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2017.02.035_bib5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nrneph.2015.193","article-title":"HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond","volume":"12","author":"Maxwell","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2017.02.035_bib6","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1097\/01.ASN.0000017223.49823.2A","article-title":"Expression of hypoxia-inducible factor-1\u03b1 and -2\u03b1 in hypoxic and ischemic rat kidneys","volume":"13","author":"Rosenberger","year":"2002","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2017.02.035_bib7","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1073\/pnas.0608382104","article-title":"Acute postnatal ablation of Hif-2\u03b1 results in anemia","volume":"104","author":"Gruber","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.kint.2017.02.035_bib8","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s00424-016-1829-2","article-title":"Erythropoietin production by PDGFR-\u03b2+ cells","volume":"468","author":"Gerl","year":"2016","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.kint.2017.02.035_bib9","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJMoa073123","article-title":"A\u00a0Gain-of-function mutation in the HIF2A gene in familial erythrocytosis","volume":"358","author":"Percy","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2017.02.035_bib10","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1093\/emboj\/cdg392","article-title":"HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1\u03b1 in normoxia","volume":"22","author":"Berra","year":"2003","journal-title":"EMBO J"},{"key":"10.1016\/j.kint.2017.02.035_bib11","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2007-10-117812","article-title":"Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure","volume":"111","author":"Minamishima","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.kint.2017.02.035_bib12","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1073\/pnas.0508423103","article-title":"A\u00a0family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis","volume":"103","author":"Percy","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.kint.2017.02.035_bib13","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/nm.3218","article-title":"Origin and function of myofibroblasts in kidney fibrosis","volume":"19","author":"LeBleu","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2017.02.035_bib14","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1681\/ASN.2013010030","article-title":"Plasticity of renal erythropoietin-producing cells governs fibrosis","volume":"24","author":"Souma","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2017.02.035_bib15","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1681\/ASN.2014121184","article-title":"Erythropoietin synthesis in renal myofibroblasts is restored by activation of hypoxia signaling","volume":"27","author":"Souma","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2017.02.035_bib16","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1681\/ASN.2015030241","article-title":"Roxadustat (FG-4592): correction of anemia in incident dialysis patients","volume":"27","author":"Besarab","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2017.02.035_bib17","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/ndt\/gfv302","article-title":"Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients","volume":"30","author":"Besarab","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2017.02.035_bib18","doi-asserted-by":"crossref","first-page":"982","DOI":"10.2215\/CJN.06890615","article-title":"Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD","volume":"11","author":"Provenzano","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2017.02.035_bib19","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.kint.2016.07.019","article-title":"Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease","volume":"90","author":"Pergola","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2017.02.035_bib20","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1172\/JCI63924","article-title":"Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis","volume":"122","author":"Liu","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2017.02.035_bib21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/jnc.12804","article-title":"HIF prolyl hydroxylase inhibition prior to transient focal cerebral ischaemia is neuroprotective in mice","volume":"131","author":"Chen","year":"2014","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.kint.2017.02.035_bib22","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s00424-014-1667-z","article-title":"Pre- and post-conditional inhibition of prolyl-4-hydroxylase domain enzymes protects the heart from an ischemic insult","volume":"467","author":"Vogler","year":"2015","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.kint.2017.02.035_bib23","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1073\/pnas.0903978106","article-title":"Donor treatment with a PHD-inhibitor activating HIFs prevents graft injury and prolongs survival in an allogenic kidney transplant model","volume":"106","author":"Bernhardt","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.kint.2017.02.035_bib24","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.2337\/db14-0472","article-title":"HIF prolyl 4-hydroxylase-2 Inhibition improves glucose and lipid metabolism and protects against obesity and metabolic dysfunction","volume":"63","author":"Rahtu-Korpela","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2017.02.035_bib25","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1158\/0008-5472.CAN-10-3838","article-title":"Inhibition of HIF prolyl hydroxylase-2 blocks tumor growth in mice through the antiproliferative activity of TGF\u03b2","volume":"71","author":"Klotzsche-von Ameln","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.kint.2017.02.035_bib26","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.celrep.2015.07.010","article-title":"The cancer cell oxygen sensor PHD2 promotes metastasis via activation of cancer-associated fibroblasts","volume":"12","author":"Kuchnio","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.kint.2017.02.035_bib27","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.cell.2009.01.020","article-title":"Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization","volume":"136","author":"Mazzone","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.kint.2017.02.035_bib28","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.15252\/embr.201540107","article-title":"Hypoxia and loss of PHD2 inactivate stromal fibroblasts to decrease tumour stiffness and metastasis","volume":"16","author":"Madsen","year":"2015","journal-title":"EMBO Rep"},{"key":"10.1016\/j.kint.2017.02.035_bib29","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/ng1019","article-title":"Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia","volume":"32","author":"Ang","year":"2002","journal-title":"Nat Genet"},{"key":"10.1016\/j.kint.2017.02.035_bib30","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1182\/blood-2008-04-153718","article-title":"Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2\u03b1 mutation","volume":"112","author":"Gale","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.kint.2017.02.035_bib31","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1681\/ASN.2014111139","article-title":"Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia","volume":"27","author":"Holdstock","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2017.02.035_bib32","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1038\/labinvest.3700328","article-title":"Cobalt promotes angiogenesis via hypoxia-inducible factor and protects tubulointerstitium in the remnant kidney model","volume":"85","author":"Tanaka","year":"2005","journal-title":"Lab Invest"},{"key":"10.1016\/j.kint.2017.02.035_bib33","first-page":"3810","article-title":"Hypoxia promotes fibrogenesis in\u00a0vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition","volume":"117","author":"Higgins","year":"2007","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2017.02.035_bib34","doi-asserted-by":"crossref","first-page":"e31034","DOI":"10.1371\/journal.pone.0031034","article-title":"Renal tubular HIF-2\u03b1 expression requires VHL inactivation and causes fibrosis and cysts","volume":"7","author":"Schietke","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.kint.2017.02.035_bib35","unstructured":"ClinicalTrials.gov. Available at: https:\/\/clinicaltrials.gov. Accessed January 2,\u00a02017."},{"key":"10.1016\/j.kint.2017.02.035_bib36","first-page":"i15","article-title":"Erythropoiesis stimulating agents (ESA)\u2013na\u00efve anaemic patients with chronic kidney disease not on dialysis (CKD-ND)","volume":"31","author":"Macdougall","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2017.02.035_bib37","first-page":"i193","article-title":"Safety and efficacy of molidustat in erythropoiesis stimulating agents (ESA) pre-treated anaemic patients with chronic kidney disease not on dialysis (CKD-ND)","volume":"31","author":"Macdougall","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2017.02.035_bib38","first-page":"iii195","article-title":"JTZ-951, an oral novel HIF-PHD inhibitor, elevates hemoglobin in Japanese anemic patients with chronic kidney disease not on dialysis","volume":"30","author":"Akizawa","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2017.02.035_bib39","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/1358863X14557151","article-title":"Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease","volume":"19","author":"Olson","year":"2014","journal-title":"Vasc Med"},{"key":"10.1016\/j.kint.2017.02.035_bib40","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.kint.2016.05.020","article-title":"Hypoxia-inducible factor-1 plays a role in phosphate-induced vascular smooth muscle cell calcification","volume":"90","author":"Mokas","year":"2016","journal-title":"Kidney Int"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253817303058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253817303058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T03:15:07Z","timestamp":1627787707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253817303058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0085253817303058"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2017.02.035","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2017.02.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}